Drug Profile
Bevacizumab biosimilar - Outlook Therapeutics
Alternative Names: ONS-1045Latest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator Oncobiologics
- Developer Ligand Pharmaceuticals; Outlook Therapeutics
- Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Colorectal cancer; Lung cancer
Highest Development Phases
- No development reported Cancer; Colorectal cancer; Lung cancer